Seres Therapeutics Names Kevin Horgan as Chief Medical Officer.
M2 PHARMA-October 25, 2018-Seres Therapeutics Names Kevin Horgan as Chief Medical Officer
(C)2018 M2 COMMUNICATIONS
- US-based microbiome therapeutics platform company Seres Therapeutics, Inc. (NASDAQ: MCRB) has appointed Kevin Horgan, M.D., as executive vice president and chief medical officer, the company said.
Horgan will lead Seres' clinical development, clinical operations, regulatory affairs, and medical affairs functions. Horgan will succeed Seres' outgoing CMO, Michele Trucksis, Ph.D., M.D., who will continue to provide consulting services to the company.
Over a three-decade academic and industry career, Dr. Horgan has contributed to the development and approval of multiple therapeutics across immunology and oncology indications. Most recently, Dr.
Horgan was vice president of clinical development at AstraZeneca where he led the development of combination immune-oncology programs.
He earlier co-founded Tucana Health, a microbiome diagnostics company.
Previously, Horgan held CMO roles at Soligenix and Coronado.
Prior to those roles, he was vice president of clinical immunology at Centocor during the development and approval of Remicade, Stelara and Simponi, approved for inflammatory bowel disease indications.
Seres Therapeutics, Inc. (NASDAQ: MCRB) is a microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced.
The company's lead programme, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the US Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate ulcerative colitis.
Seres is developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. Seres is also developing SER-401 to augment the efficacy of immuno-oncology treatment.
((Comments on this story may be sent to email@example.com))